» Articles » PMID: 38124662

Post-Orgasmic Illness Syndrome Successfully Treated with Omalizumab: A Case Report

Overview
Publisher Routledge
Date 2023 Dec 21
PMID 38124662
Authors
Affiliations
Soon will be listed here.
Abstract

Post-orgasmic illness syndrome (POIS) is a rare disorder associated with a debilitating symptoms post-ejaculation associated with significant impairment in quality of life. The mechanism of the disease is unclear, but hypersensitivity to semen and/or seminal fluid has been postulated. We present a case of POIS successfully treated with omalizumab suggesting a possible role for this therapy in POIS treatment and management.

Citing Articles

A Role for IgE in Post-Orgasmic Illness Syndrome: Successful Omalizumab Treatment in Absence of Positive Skin Test to Self Semen.

Gourgy Hacohen O, Abo-Helo N, Cohen S Am J Case Rep. 2025; 26:e945529.

PMID: 39893508 PMC: 11803315. DOI: 10.12659/AJCR.945529.


Postorgasmic illness syndrome benefiting from omalizumab and antidepressant: a case report.

Okan K, Kural R, Demir M, Cot F, Dinckal M, Altay S J Med Case Rep. 2024; 18(1):632.

PMID: 39707470 PMC: 11662807. DOI: 10.1186/s13256-024-04986-2.